Abstract
BackgroundCR6086 is a novel PGE2 EP4 receptor antagonist showing favourable immunomodulatory properties, striking DMARD effects in rodents, and an anti-inflammatory activity targeted to immune-mediated diseases and distinct from that of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have